Vaginal Atrophy and UTI-Like Symptoms

Pathophysiologic Mechanisms

Low circulating estrogen levels cause atrophic changes in both vaginal and urethral tissues, as these structures share embryologic origin and estrogen receptor distribution 1, 2
Approximately 50% of postmenopausal women experience urinary tract infections and urinary urgency directly attributable to atrophic vaginitis 1, 2

Dysuria is central to UTI diagnosis with >90% accuracy when present with acute onset, but in vaginal atrophy, dysuria may be chronic and associated with vaginal irritation 3, 4
The AUA/CUA/SUFU guidelines emphasize that lack of correlation between microbiological data and symptomatic episodes should prompt consideration of alternative diagnoses like vaginal atrophy 3, 4
Patients presenting with chronic urinary symptoms should undergo detailed pelvic examination specifically evaluating for vaginal atrophy and pelvic organ prolapse 3, 4
When symptoms persist despite negative urine cultures, vaginal atrophy should be strongly considered 3, 4

Vaginal estrogen replacement is strongly recommended in postmenopausal women to prevent recurrent UTI symptoms related to atrophy 5
For women with urinary symptoms and vaginal atrophy, first-line treatment includes vaginal moisturizers for daily comfort and lubricants with sexual activity, and second-line treatment includes low-dose vaginal estrogen for those not responding or with severe symptoms at presentation 6
Increased fluid intake may reduce recurrent UTI risk in premenopausal women 5

Do not repeatedly treat with antibiotics when urine cultures are negative or symptoms persist despite appropriate antimicrobial therapy—this suggests atrophic vaginitis rather than infection 3, 4
Do not assume all dysuria represents infection in postmenopausal women; chronic symptoms warrant evaluation for vaginal atrophy 1, 2
Unlike vasomotor symptoms that resolve over time, vaginal atrophy symptoms persist indefinitely and may worsen without treatment 1, 2
The number of women affected by atrophic vaginitis increases over time, particularly with aromatase inhibitor use in breast cancer patients (18% vs. 8% with tamoxifen) 1, 2